FRANKFURT, Nov 8 (Reuters) - AstraZeneca said on
Friday that safety data on roxadustat underpinned the British
drugmaker's hopes for the anaemia drug to become a standard
treatment for patients with kidney disease.
It said pooled data from several late-stage trials showed
that roxadustat did not increase the risk of potentially deadly
cardiovascular complications like heart attacks and strokes when
used instead of epo, which is the standard treatment for
dialysis patients against lack of red blood cells from kidney
disease.
(Reporting by Ludwig Burger; Editing by Elaine Hardcastle)
Astrazeneca (AZN)